PRI-724 + mFOLFOX6

PRI-724 + mFOLFOX6 is an experimental combination regimen comprising **PRI-724**, a small molecule inhibitor of the CBP/β-catenin interaction, plus **mFOLFOX6**, a standard chemotherapy combination of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU). - **PRI-724** targets the Wnt/β-catenin signaling pathway by antagonizing the interaction between CREB-binding protein (CBP) and β-catenin. This interferes with transcriptional programs involved in cancer cell proliferation, stemness, and tumor microenvironment modulation[7]. - **mFOLFOX6** is a widely used chemotherapy protocol primarily for metastatic colorectal cancer; it acts as a cytotoxic regimen by inducing DNA damage (via oxaliplatin) and inhibiting DNA/RNA synthesis (via 5-FU and leucovorin)[4][8]. - The combination is being investigated for enhanced anti-tumor activity, particularly to potentially overcome chemotherapy resistance mechanisms observed in colorectal and other solid tumors[1][5][7].